Edition:
India

PTC Therapeutics Inc (PTCT.OQ)

PTCT.OQ on NASDAQ Stock Exchange Global Select Market

16.13USD
15 Dec 2017
Change (% chg)

$0.18 (+1.13%)
Prev Close
$15.95
Open
$15.99
Day's High
$16.47
Day's Low
$15.80
Volume
1,585,741
Avg. Vol
344,392
52-wk High
$21.94
52-wk Low
$8.14

Latest Key Developments (Source: Significant Developments)

PTC Therapeutics reports qtrly net loss per share basic and diluted of $0.82
Friday, 3 Nov 2017 

Nov 2 (Reuters) - Ptc Therapeutics Inc ::Qtrly total revenues $41.9 million versus $22.98 million.Qtrly net loss per share basic and diluted $0.82.Q3 earnings per share view $-0.68, revenue view $42.2 million -- Thomson Reuters I/B/E/S.Increasing 2017 revenue guidance to $160-$185M​.FY2017 revenue view $173.4 million -- Thomson Reuters I/B/E/S.  Full Article

Camber Capital Management LLC reports 5.84 pct passive stake in PTC Therapeutics
Thursday, 29 Sep 2016 

Camber Capital Management LLC:Camber Capital Management LLC reports 5.84 pct passive stake in PTC Therapeutics Inc as of Sept. 19 - SEC filing.  Full Article

PTC Therapeutics qtrly Translarna net sales of $15.4 mln
Friday, 5 Aug 2016 

PTC Therapeutics Inc : Says full-year Translarna net sales on-track to meet guidance of $65m to $85m . Says ema review of european marketing authorization for translarna continues .Qtrly Translarna net sales of $15.4m.  Full Article

PTC Therapeutics provides regulatory update on Translarna
Monday, 25 Jul 2016 

: Says no longer anticipates that chmp will issue its opinion regarding ema approval of translarna in mid-2016 . Says confirmatory phase 3 act cf trial of translarna is currently ongoing . Says there is substantial risk that results from translarna trial, expected in early 2017, will be required for approval . Ptc therapeutics provides regulatory update on translarna™ (ataluren) . Ptc Therapeutics Inc Says Company Has Been Informed That Renewal Assessment Procedure Cannot Be Completed By Mid Year 2016 . Expects translarna's current marketing authorization status will remain valid until a decision is adopted by european commission .Chmp has agreed to proposal by ptc to submit a draft clinical trial protocol for translarna for further discussion.  Full Article

PTC Therapeutics and NHS England negotiate managed access agreement
Thursday, 7 Jul 2016 

PTC Therapeutics Inc : Co and NHS England negotiate managed access agreement translarna for patients with nonsense mutation duchenne muscular dystrophy .Decision provides reimbursed patient access to translarna in england via a five-year MAA.  Full Article

PTC Therapeutics announces workforce reduction as part of operating expense management plan
Thursday, 24 Mar 2016 

PTC Therapeutics:Company is reducing its workforce by approximately 18%, which will primarily affect employees and contractors in the U.S.Reduction is part of PTC's program intended to optimally manage operating expenses following its recent setback related to refuse to file letter received from U.S. Food and Drug Administration for Translarna for treatment of nonsense mutation Duchenne muscular dystrophy.Intends to work with the FDA to determine best path forward to bring Translarna to patients in U.S.Plans to complete this workforce reduction by June 30.Expects to incur related employee severance and benefit costs of approximately $2.5 million.  Full Article

FDA declines to approve PTC's Duchenne drug

The U.S. Food and Drug Administration has declined to approve PTC Therapeutics Inc's experimental drug to treat Duchenne muscular dystrophy, saying an additional clinical trial would be needed to prove the drug works.